Bioneer Corporation (064550.KQ)
KRW 19520.0
(-3.84%)
KRW 19520.0
(-3.84%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 263.23 Billion KRW | 20.53% |
| 2022 | 218.39 Billion KRW | -2.39% |
| 2021 | 223.74 Billion KRW | 8.1% |
| 2020 | 206.98 Billion KRW | 470.33% |
| 2019 | 36.29 Billion KRW | 50.73% |
| 2018 | 24.07 Billion KRW | 3.48% |
| 2017 | 23.26 Billion KRW | 7.21% |
| 2016 | 21.7 Billion KRW | 4.18% |
| 2015 | 20.83 Billion KRW | 16.69% |
| 2014 | 17.85 Billion KRW | -25.31% |
| 2013 | 23.9 Billion KRW | 16.41% |
| 2012 | 20.53 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 78.44 Billion KRW | -0.97% |
| 2024 Q3 | 65.87 Billion KRW | -16.01% |
| 2024 Q1 | 79.21 Billion KRW | 23.55% |
| 2023 Q4 | 64.11 Billion KRW | -13.05% |
| 2023 Q1 | 56.02 Billion KRW | 12.53% |
| 2023 Q3 | 73.74 Billion KRW | 6.33% |
| 2023 FY | 263.23 Billion KRW | 20.53% |
| 2023 Q2 | 69.34 Billion KRW | 23.77% |
| 2022 Q3 | 54.59 Billion KRW | 3.86% |
| 2022 Q2 | 52.56 Billion KRW | -14.47% |
| 2022 FY | 218.39 Billion KRW | -2.39% |
| 2022 Q1 | 61.45 Billion KRW | 10.2% |
| 2022 Q4 | 49.78 Billion KRW | -8.8% |
| 2021 Q3 | 63.98 Billion KRW | 18.26% |
| 2021 Q2 | 54.1 Billion KRW | 8.47% |
| 2021 Q4 | 55.76 Billion KRW | -12.85% |
| 2021 FY | 223.74 Billion KRW | 8.1% |
| 2021 Q1 | 49.88 Billion KRW | -18.78% |
| 2020 Q2 | 59.27 Billion KRW | 370.22% |
| 2020 Q3 | 73.69 Billion KRW | 24.34% |
| 2020 Q4 | 61.41 Billion KRW | -16.66% |
| 2020 Q1 | 12.6 Billion KRW | 71.96% |
| 2020 FY | 206.98 Billion KRW | 470.33% |
| 2019 Q1 | 6.78 Billion KRW | -6.93% |
| 2019 FY | 36.29 Billion KRW | 50.73% |
| 2019 Q4 | 7.32 Billion KRW | -34.01% |
| 2019 Q2 | 11.06 Billion KRW | 63.16% |
| 2019 Q3 | 11.1 Billion KRW | 0.35% |
| 2018 Q4 | 7.28 Billion KRW | 26.26% |
| 2018 Q2 | 6.67 Billion KRW | 53.83% |
| 2018 Q1 | 4.33 Billion KRW | -24.95% |
| 2018 FY | 24.07 Billion KRW | 3.48% |
| 2018 Q3 | 5.77 Billion KRW | -13.51% |
| 2017 Q1 | 5.86 Billion KRW | -9.34% |
| 2017 FY | 23.26 Billion KRW | 7.21% |
| 2017 Q4 | 5.78 Billion KRW | -4.69% |
| 2017 Q2 | 5.55 Billion KRW | -5.23% |
| 2017 Q3 | 6.06 Billion KRW | 9.18% |
| 2016 FY | 21.7 Billion KRW | 4.18% |
| 2016 Q1 | 4.48 Billion KRW | -25.4% |
| 2016 Q2 | 5.68 Billion KRW | 26.76% |
| 2016 Q4 | 6.46 Billion KRW | 27.44% |
| 2016 Q3 | 5.07 Billion KRW | -10.67% |
| 2015 Q4 | 6 Billion KRW | 4.93% |
| 2015 Q2 | 4.96 Billion KRW | 20.18% |
| 2015 Q1 | 4.13 Billion KRW | -22.98% |
| 2015 FY | 20.83 Billion KRW | 16.69% |
| 2015 Q3 | 5.72 Billion KRW | 15.25% |
| 2014 Q3 | 4.14 Billion KRW | -1.47% |
| 2014 Q1 | 4.12 Billion KRW | -22.59% |
| 2014 FY | 17.85 Billion KRW | -25.31% |
| 2014 Q4 | 5.36 Billion KRW | 29.38% |
| 2014 Q2 | 4.2 Billion KRW | 1.96% |
| 2013 Q2 | 6.46 Billion KRW | 10.47% |
| 2013 Q4 | 5.33 Billion KRW | -14.67% |
| 2013 Q3 | 6.25 Billion KRW | -3.34% |
| 2013 Q1 | 5.85 Billion KRW | -15.57% |
| 2013 FY | 23.9 Billion KRW | 16.41% |
| 2012 FY | 20.53 Billion KRW | 0.0% |
| 2012 Q4 | 6.93 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| HLB Co., Ltd. | 42.9 Billion KRW | -513.598% |
| iNtRON Biotechnology, Inc. | 9.58 Billion KRW | -2646.214% |
| BINEX Co., Ltd. | 154.82 Billion KRW | -70.022% |
| Anterogen.Co.,Ltd. | 6.5 Billion KRW | -3949.641% |
| MEDIPOST Co., Ltd. | 68.64 Billion KRW | -283.487% |
| CrystalGenomics, Inc. | 4.87 Billion KRW | -5295.675% |
| Helixmith Co., Ltd | 4.2 Billion KRW | -6165.122% |
| Chabiotech Co.,Ltd. | 953.95 Billion KRW | 72.406% |
| Medy-Tox Inc. | 221.12 Billion KRW | -19.047% |
| Peptron, Inc. | 3.34 Billion KRW | -7776.876% |
| Amicogen, Inc. | 159.9 Billion KRW | -64.621% |
| Genexine, Inc. | 4.42 Billion KRW | -5846.668% |
| HLB Therapeutics Co.,Ltd. | 53.74 Billion KRW | -389.751% |
| LegoChem Biosciences, Inc. | 34.14 Billion KRW | -670.924% |
| ALTEOGEN Inc. | 96.52 Billion KRW | -172.719% |
| PharmaResearch Co., Ltd. | 261.01 Billion KRW | -0.853% |
| SillaJen, Inc. | 3.93 Billion KRW | -6581.886% |
| JETEMA, Co., Ltd. | 58.71 Billion KRW | -348.322% |
| OliX Pharmaceuticals,Inc | 17.06 Billion KRW | -1442.619% |
| Genomictree Inc. | 3.41 Billion KRW | -7601.465% |
| MedPacto, Inc. | - KRW | -Infinity% |
| D&D Pharmatech | 18.67 Billion KRW | -1309.413% |
| EASY BIO,Inc. | 165.38 Billion KRW | -59.166% |
| GI Innovation, Inc. | 5.31 Billion KRW | -4849.131% |